Presenting at AHS 2022, researchers evaluated the safety and efficacy of eptinezumab for migraine in patients with episodic and chronic migraine with prior treatment failures.

Presenting at AHS 2022, researchers examined the effects of supplementation of B vitamins and a combination of these vitamins on women with episodic migraine.

Presenting at AHS 2022, researchers assessed the efficacy of galcanezumab 120 mg/month in the prevention of episodic migraine.

Presenting at AHS 2022, researchers determined the effect of generalized anxiety disorder on the responsiveness of BoNT-A treatment from pediatric patients with chronic migraine.

Presenting at AHS 2022, researchers assessed the effect of a high-fat meal on the pharmacokinetics of immediate release atogepant tablets.